Further studies demonstrated that these mutations in CYLD/TRAF3, or the loss of TRAF3, resulted in enhanced NFκB signalling and promoted HPV+ HNSCC [105,110]. This evidence concerns the gene TRAF3 and head and neck squamous cell carcinoma.